BG105715A - Combination chemotherapy - Google Patents

Combination chemotherapy

Info

Publication number
BG105715A
BG105715A BG105715A BG10571501A BG105715A BG 105715 A BG105715 A BG 105715A BG 105715 A BG105715 A BG 105715A BG 10571501 A BG10571501 A BG 10571501A BG 105715 A BG105715 A BG 105715A
Authority
BG
Bulgaria
Prior art keywords
combination chemotherapy
combination
paclitaxel
meanings
substituents
Prior art date
Application number
BG105715A
Other languages
Bulgarian (bg)
English (en)
Inventor
Richard Gowan
- LEOPOLD Judith SEBOLT
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG105715A publication Critical patent/BG105715A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG105715A 1998-12-22 2001-07-18 Combination chemotherapy BG105715A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10
PCT/US1999/030485 WO2000037141A1 (en) 1998-12-22 1999-12-21 Combination chemotherapy

Publications (1)

Publication Number Publication Date
BG105715A true BG105715A (en) 2002-04-30

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105715A BG105715A (en) 1998-12-22 2001-07-18 Combination chemotherapy

Country Status (31)

Country Link
EP (1) EP1140291B1 (tr)
JP (1) JP2002532570A (tr)
KR (1) KR20010099877A (tr)
CN (1) CN1333698A (tr)
AP (1) AP2001002175A0 (tr)
AT (1) ATE310567T1 (tr)
AU (1) AU2203900A (tr)
BG (1) BG105715A (tr)
BR (1) BR9916839A (tr)
CA (1) CA2352326A1 (tr)
CZ (1) CZ20012139A3 (tr)
DE (1) DE69928568T2 (tr)
EA (1) EA200100687A1 (tr)
EE (1) EE200100339A (tr)
ES (1) ES2253928T3 (tr)
GE (1) GEP20043172B (tr)
HK (1) HK1042057A1 (tr)
HR (1) HRP20010473A2 (tr)
HU (1) HUP0104844A3 (tr)
ID (1) ID30250A (tr)
IL (1) IL143939A0 (tr)
IS (1) IS5969A (tr)
MA (1) MA26768A1 (tr)
NO (1) NO20013099L (tr)
NZ (1) NZ512859A (tr)
OA (1) OA11733A (tr)
PL (1) PL348326A1 (tr)
SK (1) SK8712001A3 (tr)
TR (1) TR200101871T2 (tr)
WO (1) WO2000037141A1 (tr)
YU (1) YU45401A (tr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
CA2419567A1 (en) 2000-09-01 2002-03-07 George Vande Woude Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
EP1377312A4 (en) * 2001-03-22 2004-10-06 Andel Inst Van ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
WO2005035493A1 (ja) * 2003-10-08 2005-04-21 Teijin Pharma Limited アミノピロリジン誘導体の製造方法および中間体化合物
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
EA013212B1 (ru) 2004-10-20 2010-04-30 Лаборатуар Сероно Са 3-ариламинопиридиновые производные
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
CA2927656C (en) 2005-10-07 2019-09-24 Exelixis, Inc. Mek inhibitors and methods of their use
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
MX2015004660A (es) 2012-10-12 2015-08-07 Exelixis Inc Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer.
JP6465790B2 (ja) * 2013-02-27 2019-02-06 第一三共株式会社 Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
JP2001517954A (ja) * 1997-03-21 2001-10-09 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｏｅｙ２遺伝子組成物およびその使用方法
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
ES2253928T3 (es) 2006-06-01
EP1140291B1 (en) 2005-11-23
HUP0104844A3 (en) 2003-05-28
NZ512859A (en) 2004-06-25
CA2352326A1 (en) 2000-06-29
HRP20010473A2 (en) 2002-08-31
IS5969A (is) 2001-06-14
SK8712001A3 (en) 2002-02-05
ATE310567T1 (de) 2005-12-15
EP1140291A1 (en) 2001-10-10
YU45401A (sh) 2004-07-15
NO20013099L (no) 2001-08-20
WO2000037141A9 (en) 2000-12-07
KR20010099877A (ko) 2001-11-09
DE69928568T2 (de) 2006-07-27
IL143939A0 (en) 2002-04-21
EA200100687A1 (ru) 2001-12-24
OA11733A (en) 2005-05-12
TR200101871T2 (tr) 2001-10-22
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
AU2203900A (en) 2000-07-12
AP2001002175A0 (en) 2001-06-21
CN1333698A (zh) 2002-01-30
JP2002532570A (ja) 2002-10-02
DE69928568D1 (de) 2005-12-29
HK1042057A1 (zh) 2002-08-02
MA26768A1 (fr) 2004-12-20
CZ20012139A3 (cs) 2002-01-16
WO2000037141A1 (en) 2000-06-29
NO20013099D0 (no) 2001-06-21
PL348326A1 (en) 2002-05-20
BR9916839A (pt) 2001-10-09
ID30250A (id) 2001-11-15
EE200100339A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
BG105715A (en) Combination chemotherapy
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
AP2001002103A0 (en) Substituted phenyl derivatives, their preparation and use.
DE69713402T2 (de) Liganden des neuropeptids y
GEP20074185B (en) Incclusion complexs of aryl- heterocyclic salts
BG103413A (en) Derivatives of sulphinic acid, their production and application
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
CY2509B1 (en) New thiazole derivatives with phosphodiesterase-inhibitting effect
WO1999050255A3 (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
IL145639A0 (en) C10 heterosubstituted acetate taxanes as antitumor agents
PL343374A1 (en) Anti-inflammatory, antibacterial benzyl phenol agents
SI1086096T1 (en) Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
MX9708827A (es) Derivados novedosos de amidina utiles como inhibidores de agregacion plaquetaria y como vasodilatadores.
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
IL153352A0 (en) Coumarin derivatives with comt inhibiting activity
AP2001002045A0 (en) FKBP inhibitors.
GB2324091A (en) Metalloproteinase inhibitors
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
MXPA05006957A (es) Nuevos derivados de fosforamida.
WO2000035428A3 (de) Tricyclische stickstoffheterocyclen als pde iv inhibitoren
BG105966A (en) C7 carbonate substituted taxanes and their application as antitumor agents
BG105252A (en) Isoquinolines as urokinase inhibitors
BG105965A (en) C10 ester substituted taxanes and their application as antitumor agents
MX9602949A (es) 2-oxa y tia-zolinas artropodicidas.
RS20050181A (en) Novel benzonaphthyridines